PT3205653T - Forma cristalina de bissulfato do inibidor da jak e seu método de preparação - Google Patents

Forma cristalina de bissulfato do inibidor da jak e seu método de preparação

Info

Publication number
PT3205653T
PT3205653T PT158494690T PT15849469T PT3205653T PT 3205653 T PT3205653 T PT 3205653T PT 158494690 T PT158494690 T PT 158494690T PT 15849469 T PT15849469 T PT 15849469T PT 3205653 T PT3205653 T PT 3205653T
Authority
PT
Portugal
Prior art keywords
bisulfate
preparation
crystal form
method therefor
jak inhibitor
Prior art date
Application number
PT158494690T
Other languages
English (en)
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of PT3205653T publication Critical patent/PT3205653T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT158494690T 2014-10-09 2015-09-09 Forma cristalina de bissulfato do inibidor da jak e seu método de preparação PT3205653T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410529863.8A CN105566327A (zh) 2014-10-09 2014-10-09 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法

Publications (1)

Publication Number Publication Date
PT3205653T true PT3205653T (pt) 2020-12-15

Family

ID=55652569

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158494690T PT3205653T (pt) 2014-10-09 2015-09-09 Forma cristalina de bissulfato do inibidor da jak e seu método de preparação

Country Status (15)

Country Link
US (1) US10150770B2 (pt)
EP (1) EP3205653B1 (pt)
JP (1) JP6830888B2 (pt)
KR (1) KR20170057441A (pt)
CN (2) CN105566327A (pt)
AU (1) AU2015330554B2 (pt)
BR (1) BR112017005564A2 (pt)
CA (1) CA2963581C (pt)
DK (1) DK3205653T3 (pt)
ES (1) ES2836100T3 (pt)
HU (1) HUE052924T2 (pt)
PT (1) PT3205653T (pt)
RU (1) RU2704795C2 (pt)
TW (1) TWI675839B (pt)
WO (1) WO2016054959A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047404T2 (hu) 2014-11-05 2020-04-28 Jiangsu Hengrui Medicine Co JAK kináz inhibitor biszulfát kristályos alakja és eljárás elõállítására
KR20180109992A (ko) 2016-02-19 2018-10-08 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Jak 키나아제 억제제 또는 약학적으로 허용가능한 그의 염을 함유하는 약학적 조성물
HUE055530T2 (hu) * 2016-11-23 2021-12-28 Wuxi Fortune Pharmaceutical Co Ltd 7H-pirrolo[2,3-D]pirimidin vegyület kristály formája és só formája, és ezek elkészítési eljárása
WO2018133823A1 (zh) * 2017-01-20 2018-07-26 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
AU2021318201A1 (en) 2020-07-28 2023-02-02 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
WO2022108911A1 (en) 2020-11-17 2022-05-27 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
WO2023016551A1 (zh) * 2021-08-12 2023-02-16 江苏恒瑞医药股份有限公司 用于治疗或预防抗宿主病的吡咯并六元杂芳物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74370C2 (uk) * 2000-06-26 2005-12-15 Пфайзер Продактс Інк. Піроло(2,3-d)піримідинові сполуки як імуносупресори
GB0307856D0 (en) 2003-04-04 2003-05-14 Novartis Ag Organic compounds
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
EP1846359A4 (en) * 2005-01-06 2010-03-31 Cj Cheiljedang Corp INORGANIC ACID SALTS OF SIBUTRAMINE
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2012135338A1 (en) * 2011-03-28 2012-10-04 Ratiopharm Gmbh Processes for preparing tofacitinib salts
SI2796460T1 (sl) * 2011-12-21 2018-10-30 Jiangsu Hengrui Medicine Co. Ltd Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
US9422300B2 (en) * 2013-06-07 2016-08-23 Jiangsu Hengrui Medicine Co., Ltd. Bisulfate of janus kinase (JAK) inhibitor and preparation method therefor

Also Published As

Publication number Publication date
EP3205653B1 (en) 2020-11-25
WO2016054959A1 (zh) 2016-04-14
CN105566327A (zh) 2016-05-11
CA2963581A1 (en) 2016-04-14
BR112017005564A2 (pt) 2017-12-12
KR20170057441A (ko) 2017-05-24
TW201613931A (en) 2016-04-16
RU2704795C2 (ru) 2019-10-31
ES2836100T3 (es) 2021-06-24
US10150770B2 (en) 2018-12-11
DK3205653T3 (da) 2021-01-11
CN105980389A (zh) 2016-09-28
CN105980389B (zh) 2017-12-19
HUE052924T2 (hu) 2021-06-28
AU2015330554B2 (en) 2020-01-02
JP2017530146A (ja) 2017-10-12
RU2017114689A (ru) 2018-11-14
RU2017114689A3 (pt) 2019-01-22
AU2015330554A1 (en) 2017-04-27
CA2963581C (en) 2022-07-12
JP6830888B2 (ja) 2021-02-17
TWI675839B (zh) 2019-11-01
EP3205653A4 (en) 2018-06-20
EP3205653A1 (en) 2017-08-16
US20180237438A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
IL258276A (en) Crystal forms of beta-nicotinamide mononucleotide
ZA201703075B (en) Substituted chromanes and method of use
SG10201510712PA (en) Etchant solutions and method of use thereof
GB201514756D0 (en) Compound and method of use
IL250391B (en) Crystalline forms of glutaminase inhibitors
IL251988A0 (en) Compounds acting on glycans and methods of using them
GB201514760D0 (en) Compounds and method of use
HUE052924T2 (hu) A JAK gátló biszulfátjának kristályos formája és annak elõkészítési eljárása
EP3269719A4 (en) Crystal form of jak inhibitor and preparation method thereof
PL3089971T3 (pl) Związki i sposoby ich zastosowania
GB2528136B (en) User-adjustable headband and method of manufacture thereof
GB201521822D0 (en) Devices and method of operation thereof
IL253018A0 (en) Crystalline forms of apomorphine and their uses
GB201406135D0 (en) Method of etching
SI3216790T1 (sl) Kristalinična oblika bisulfata inhibitorja JAK-kinaze in postopek priprave le-te
TWI563617B (en) Substrate structure and method of manufacture
EP3176814C0 (en) PHOTODETECTOR ARRANGEMENTS AND METHODS OF MAKING SAME
SG11201608466XA (en) Perforated substrate and a method of manufacture
GB201403697D0 (en) Compounds and methods of use
GB201419990D0 (en) Hprseshoe and method of manufacture
GB201416797D0 (en) Contianer and method of use thereof
GB201507707D0 (en) Components and methods for formation of components
SG10201401365VA (en) Perforated substrate and a method of manufacture